Literature DB >> 2142173

Evaluation of skin test reactions in patients with non-immediate type drug eruptions.

J Osawa1, S Naito, M Aihara, K Kitamura, Z Ikezawa, H Nakajima.   

Abstract

Skin test reactions were evaluated in 242 patients who appeared to develop delayed type drug eruptions from the clinical course. The patch testing was positive in 62 (31.5%) of 197 patients tested and the intradermal testing in 105 (89.7%) of 117 patients. The positive ratios of intradermal testing were higher in maculopapular (MP), erythema multiforme (EM), and erythrodermic (ED) types than in eczematous (Ecz) type drug eruptions, while those of patch testing were comparatively high in ED, Ecz type, and anticonvulsant-induced drug eruptions. It is considered that the combination of patch testing and intradermal testing is useful for determination of causative drugs in delayed type drug eruptions.

Entities:  

Mesh:

Year:  1990        PMID: 2142173     DOI: 10.1111/j.1346-8138.1990.tb01631.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  11 in total

Review 1.  Eczematous Drug Eruptions.

Authors:  Amy E Blum; Susan Burgin
Journal:  Am J Clin Dermatol       Date:  2021-02-15       Impact factor: 7.403

2.  Patch testing in non-immediate drug eruptions.

Authors:  Antonino Romano; Marinella Viola; Francesco Gaeta; Gabriele Rumi; Michela Maggioletti
Journal:  Allergy Asthma Clin Immunol       Date:  2008-06-15       Impact factor: 3.406

3.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02

Review 4.  Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 5.  Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.

Authors:  Katherine C Konvinse; Elizabeth J Phillips; Katie D White; Jason A Trubiano
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

6.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 7.  Cellular in vitro diagnosis of adverse drug reactions.

Authors:  Christian Möbs; Wolfgang Pfützner
Journal:  Allergo J Int       Date:  2014-08-07

Review 8.  An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity.

Authors:  Ana Copaescu; Andrew Gibson; Yueran Li; Jason A Trubiano; Elizabeth J Phillips
Journal:  Front Pharmacol       Date:  2021-01-12       Impact factor: 5.810

9.  COVID-19 mRNA Vaccine-induced Pneumonitis.

Authors:  Shinichi Matsuzaki; Hiroyuki Kamiya; Ichiro Inoshima; Yasutaka Hirasawa; Osamu Tago; Masashi Arai
Journal:  Intern Med       Date:  2021-10-26       Impact factor: 1.271

10.  Intradermal Tests for Diagnosis of Drug Allergy are not Affected by a Topical Anesthetic Patch.

Authors:  Mariana Couto; Diana Silva; Ana Ferreira; Josefina R Cernadas
Journal:  Allergy Asthma Immunol Res       Date:  2014-06-18       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.